NRX Pharmaceuticals

Company snapshot

NRX Pharmaceuticals is a pharma organization headquartered in WILMINGTON, DE, USA. It trades on NYSE under ticker NRXP. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 1 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• 1 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for NRX Pharmaceuticals. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for NRX Pharmaceuticals.

1. Feb 16, 2010 Patent grant

   Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon

View all clinical trial activity →

• What is NRX Pharmaceuticals?

  NRX Pharmaceuticals is a pharma organization headquartered in WILMINGTON, DE, USA. It trades on NYSE under ticker NRXP. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 1 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources

• Is NRX Pharmaceuticals publicly traded?

  Yes. NRX Pharmaceuticals is listed with ticker NRXP on NYSE per SEC EDGAR records linked on this profile.

• What drugs does NRX Pharmaceuticals develop or market?

  No drug profiles are currently linked to NRX Pharmaceuticals. Pipeline programs may still list investigational assets.

• What are the latest developments for NRX Pharmaceuticals?

  Browse related news and pipeline sections on this page for coverage and ClinicalTrials.gov-linked program updates.

• What therapeutic areas does NRX Pharmaceuticals focus on?

  No specific therapeutic focus areas are currently identified for NRX Pharmaceuticals in our database.